Optimized Cardiopulmonary Bypass Flow Strategy Based on Ideal Body Weight in Obese Patients Undergoing Cardiac Surgery (IDEALFLOW)
Cardiopulmonary bypass (CPB) pump flow is typically calculated according to body surface area (BSA) derived from actual body weight and temperature, following the 2024 European guidelines recommending an indexed flow of 2.4 L/min/m². However, in obese patients, using actual weight leads to a high BSA and thus elevated pump flow, increasing technical challenges such as the need for larger cannulas, higher circulating blood volume, and elevated pump speeds. These adjustments may increase risks of hemodilution, transfusion, and hemolysis. Given that lean body mass in obese patients is similar to that of non-obese patients of the same height-and that aerobic metabolism depends on lean mass-adjusting CPB flow based on ideal body weight rather than actual weight could reduce transfusions and associated complications. Several observational studies support the concept of using ideal body weight for CPB flow calculation in obese patients. Despite this, no randomized controlled trial has yet addressed the clinical impact of this approach. Given the increasing prevalence of obesity and the practical challenges it poses during cardiac surgery, a controlled clinical trial is warranted.
The investigators hypothesize that adjusting the cardiopulmonary bypass (CPB) flow according to the ideal body weight rather than the actual body weight in obese patients could reduce the need for blood transfusions and limit the associated complications.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Osama ABOU ARAB, Pr
- Phone Number: 33+3 22 08 78 36
- Email: AbouArab.Osama@chu-amiens.fr
Study Locations
-
-
-
Amiens, France, 80054
- Recruiting
- CHU Amiens Picardie
-
Contact:
- Osama ABOU ARAB, MD
- Phone Number: +33322087836
- Email: abouarab.osama@chu-amiens.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients aged over 18 years
- Patients with obesity (BMI > 30 kg/m²)
- Scheduled cardiac surgery under cardiopulmonary bypass (CPB):
- Coronary artery bypass grafting (CABG)
- Aortic valve replacement
- Mitral valve repair or replacement
- Surgery on the aortic root (aortic tube, Bentall procedure, Tirone David, or others)
- Combined surgery
- Affiliation to a social security scheme
- Written informed consent
Exclusion Criteria:
- Minors
- BMI < 30 kg/m²
- Off-pump cardiac surgery
- Surgery on the aortic arch
- Planned perioperative hypothermia < 32ºC
- Emergency surgery
- Heart transplantation or mechanical circulatory support surgery
- Infectious endocarditis
- Participation in another clinical trial within the past 30 days
- Pregnant, parturient, or breastfeeding women
- Patients under guardianship, curatorship, or deprived of civil rights
- Advanced chronic kidney disease (renal clearance < 30 ml/min)
- Coexisting disease with a high probability of death within 6 months
- Preoperative anemia (hemoglobin < 10 g/dL)
- Body surface area (actual body weight) > 2.5 m²
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: body surface area (BSA) calculated from ideal body weight
Cardiac surgery under cardiopulmonary bypass (CPB) with CPB flow indexed at 2.4 ml/min/m², using body surface area (BSA) calculated from ideal body weight (Lorentz formula) |
CPB is standardized according to the following protocol:
Anticoagulation will be managed according to center practices to maintain an activated clotting time (ACT) > 400 seconds, in accordance with recommendations. |
|
Active Comparator: BSA calculated from actual body weight.
Cardiac surgery under CPB with CPB flow indexed at 2.4 ml/min/m², using BSA calculated from actual body weight. |
CPB is standardized according to the following protocol:
Anticoagulation will be managed according to center practices to maintain an activated clotting time (ACT) > 400 seconds, in accordance with recommendations. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
reduction in the incidence of erythrocyte concentrates transfused
Time Frame: 1 day
|
reduction in the incidence of erythrocyte concentrates transfused from the start to the end of cardiopulmonary bypass (CPB) |
1 day
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
hematocrit measurement during CPB
Time Frame: 1 day
|
Hemodilution quantified by hematocrit measurement during CPB |
1 day
|
|
Number of platelet concentrates administered during CPB
Time Frame: 1 day
|
Number of platelet concentrates administered during CPB |
1 day
|
|
Number of fresh frozen plasma units administered during CPB
Time Frame: 1 day
|
Number of fresh frozen plasma units administered during CPB |
1 day
|
|
Number of labile blood products administered during the entire ICU stay
Time Frame: 1 day
|
Number of labile blood products administered during the entire ICU stay |
1 day
|
|
Number of Acute kidney injury
Time Frame: within 7 days
|
Acute kidney injury defined according to KDIGO criteria by an increase in serum creatinine ≥26.5 μmol/L or at least 1.5 times the baseline value within 7 days after surgery compared to the preoperative baseline |
within 7 days
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- PI2026_843_0111
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.